SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                FORM 10-Q/A No. 1

(Mark One)
[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
     ACT OF 1934

For the Quarterly Period Ended June 30, 2001

                                       OR

[ ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D)OF THE SECURITIES EXCHANGE
     ACT OF 1934

For the Transition Period from                       to

                                    001-14665
                             COMMISSION FILE NUMBER

                               CLAIMSNET.COM INC.

             (Exact name of registrant as specified in its charter)

          Delaware                                         75-2649230

(State or other jurisdiction of                        (I.R.S. Employer
 incorporation or organization)                        Identification No.)

  12801 N. Central Expressway, Suite 1515
  Dallas, Texas                                                  75243

    (Address of principal                                     (Zip Code)
      executive offices)

Registrant's telephone number, including area code:   972-458-1701

Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date. Common Stock, $.001 par value,
10,481,514 shares outstanding as of October 2, 2001.

<PAGE>



                        CLAIMSNET.COM INC. AND SUBSIDIARY

                                TABLE OF CONTENTS




PART I.  FINANCIAL INFORMATION

     ITEM 1.   Financial Statements

               Condensed Consolidated Balance Sheets as of June 30, 2001
               (unaudited) and December 31, 2000

               Condensed Consolidated Statements of Operations (unaudited) for
               the Three Months Ended June 30, 2001 and 2000, and for the Six
               Months Ended June 30, 2001 and 2000

               Condensed Consolidated Statements of Changes in Stockholders'
               Equity (unaudited) for the Years Ended December 31, 1999 and 2000
               and the Six Months Ended June 30, 2001

               Condensed Consolidated Statements of Cash Flows (unaudited) for
               the Six Months Ended June 30, 2001 and 2000

               Notes to Condensed Consolidated Financial Statements

     ITEM 2.   Management's Discussion and Analysis of Financial Condition and
               Results of Operations


PART II.  OTHER INFORMATION

     ITEM 6.   Exhibits and Reports on Form 8-K


SIGNATURES



                                       2
<PAGE>




                          PART I. FINANCIAL INFORMATION

ITEM 1:   FINANCIAL STATEMENTS

                        CLAIMSNET.COM INC. AND SUBSIDIARY
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                        (In thousands except share data)

<TABLE>
<CAPTION>
                                                               (Unaudited)
                                                                 June 30,          December 31,
                                                                   2001               2000(1)
                                                                ----------         -----------
<S>                                                               <C>                <C>
ASSETS
CURRENT ASSETS:
   Cash                                                           $  2,486           $  1,132
   Accounts receivable, net of allowance for
     doubtful accounts of $35 and $29, respectively                    157                307
   Prepaid expenses and other current assets                           143                123
                                                                  --------           --------
       Total current assets                                          2,786              1,562
EQUIPMENT, FIXTURES AND SOFTWARE
Computer hardware and software                                       1,814              1,875
Software development costs                                           1,923              2,351
Furniture and fixtures                                                 138                125
Office equipment                                                        25                 25
                                                                  --------           --------
                                                                     3,900              4,376
Accumulated depreciation and amortization                           (3,017)            (2,862)
                                                                  --------           --------
         Total equipment, fixtures and software                        883              1,514
                                                                  --------           --------
TOTAL                                                             $  3,669           $  3,076
                                                                  ========           ========
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
   Accounts payable                                               $    449           $    434
   Accrued severance                                                   205                363
   Accrued acquisition costs                                           500                500
   Accrued payroll and other current liabilities                       364                388
   Deferred revenue                                                      3              1,225
                                                                  --------           --------
       Total current liabilities                                     1,521              2,910
                                                                  --------           --------
STOCKHOLDERS' EQUITY:
  Preferred stock, $.001 par value; 4,000,000 shares
     authorized, no shares issued and outstanding
   Common stock, $.001 par value; 40,000,000 shares
     authorized; 11,125,000 and 9,195,000 shares issued
     as of June 30, 2001 and December 31, 2000                          11                  9
  Additional capital                                                40,188             36,820
  Deferred sales discount                                                -             (1,334)
  Accumulated deficit                                              (37,025)           (34,303)
  Treasury stock, at cost - 644,000 shares as of
     June 30, 2001 and December 31, 2000                            (1,026)            (1,026)
                                                                  --------           --------
       Total stockholders' equity                                    2,148                166
                                                                  --------           --------
TOTAL                                                             $  3,669           $  3,076
                                                                  ========           ========
</TABLE>

(1)  The condensed consolidated balance sheet as of December 31, 2000 has been
     derived from the audited financial statements at that date.

            See notes to condensed consolidated financial statements.

                                       3
<PAGE>


                        CLAIMSNET.COM INC. AND SUBSIDIARY
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                      (In thousands except per share data)
                                   (Unaudited)



<TABLE>
<CAPTION>

                                                         Three Months Ended         Six Months Ended
                                                              June 30,                  June 30,
                                                   ------------------------   --------------------------
                                                      2001          2000(1)       2001           2000(1)
                                                   ----------   -----------   --------      ------------
<S>                                               <C>           <C>           <C>           <C>
REVENUES                                          $    263      $    330      $    795      $    610

COST OF REVENUES                                       565           942         1,475         1,769
                                                  --------      --------      --------      --------
GROSS LOSS                                            (302)         (612)         (680)       (1,159)
                                                  --------      --------      --------      --------
OPERATING EXPENSES:
   Research and Development                            178           753           360           984
   Purchased Research & Development                      -         6,154             -         6,154
   Amortization of Intangibles                           -           154             -           154
   Selling, General & Administrative                   946         1,655         1,704         2,913
                                                  --------      --------      --------      --------

       Total operating expenses                      1,124         8,716         2,064        10,205
                                                  --------      --------      --------      --------

LOSS FROM OPERATIONS                                (1,426)       (9,328)       (2,744)      (11,364)

OTHER INCOME (EXPENSE)
   Interest expense                                     (3)           (3)           (4)           (3)
   Interest expense - affiliate                         (4)            -            (7)            -
   Interest income                                      27            23            33           124
                                                  --------      --------      --------      --------
       Total Other Income (Expense)                     20            20            22           121
                                                  --------      --------      --------      --------

NET LOSS                                          $ (1,406)     $ (9,308)     $ (2,722)     $(11,243)
                                                  --------      --------      --------      --------


BASIC AND DILUTED NET LOSS PER COMMON SHARE       $  (0.14)     $  (1.20)     $  (0.29)     $  (1.56)
                                                  ========      ========      ========      ========

WEIGHTED AVERAGE COMMON SHARES
OUTSTANDING - BASIC AND DILUTED                     10,285         7,746         9,467         7,185
                                                  ========      ========      ========      ========
</TABLE>


(1)  The statement of operations presentation for the three months and six
     months ended June 30, 2000 has been reclassified to conform with the 2001
     presentation format.


            See notes to condensed consolidated financial statements.

                                       4
<PAGE>

                        CLAIMSNET.COM INC. AND SUBSIDIARY
      CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
   Years Ended December 31, 1999 and 2000, and Six Months Ended June 30, 2001
                                 (In thousands)
                                   (Unaudited)
<TABLE>
<CAPTION>

                                                                                                                           Total
                                                          Number                        Deferred                       Stockholders'
                                                        of Shares   Common  Additional   Sales      Accmulated Treasury   Equity
                                                       Outstanding   Stock   Capital    Discount      Deficit    Stock   (Deficit)
                                                       -----------  ------  ----------  --------    ---------- -------- -----------
<S>                                                         <C>       <C>   <C>        <C>         <C>          <C>        <C>
Balances at December 31, 1998                               3,625     $ 4   $  3,882   $      -    $ (7,750)    $    -     $ (3,864)

Issuance of common stock with
 Series A 12% Subordinated Notes                              125       -        850          -           -           -         850

Non-employee stock option grants                                -       -        155          -           -           -         155

Issuance of common stock warrants                               -       -        121          -           -           -         121

Sale of common stock in initial public offering             2,875       3     19,512          -           -           -      19,515

Issuance of warrants in connection with
 development agreement                                          -       -      1,700     (1,700)          -           -           -

Amortization of deferred  sales discount                        -       -          -         52           -           -          52

Net loss                                                        -       -          -          -      (8,858)          -      (8,858)

                                                           ------    ----   --------    -------    --------    --------    --------
Balances at December 31, 1999                               6,625       7     26,220     (1,648)    (16,608)          -       7,971
                                                           ------    ----   --------    -------    --------    --------    --------
Sale of common stock                                        1,370       1      4,226          -           -           -       4,227

Issuance of common stock for asset purchase                 1,200       1      6,374          -           -           -       6,375

Return to treasury of stock issued for asset purchase        (888)      -          -          -           -      (1,415)     (1,415)

Issuance from treasury of common stock for
 settlement of acquired obligation                            244       -          -          -           -         389         389

Amortization of deferred sales discount                         -       -          -        314           -           -         314

Net loss                                                        -       -          -          -     (17,695)          -     (17,695)
                                                           ------    ----   --------    -------    --------    --------    --------
Balances at December 31, 2000                               8,551       9     36,820     (1,334)    (34,303)     (1,026)        166
                                                           ------    ----   --------    -------    --------    --------    --------
Sale of common stock                                        1,914       2      3,269          -           -           -       3,271

Issuance of common stock for services                          16       -         42          -           -           -          42

Issuance of common stock warrants                               -       -         57          -           -           -          57

Amortization of deferred sales discount                         -       -          -         79           -           -          79

Write down of unamortized deferred sales discount               -       -          -      1,255           -           -       1,255

Net loss                                                        -       -          -          -      (2,722)          -      (2,722)
                                                           ------    ----   --------    -------    --------    --------    --------
Balances at June 30, 2001                                  10,481    $ 11   $ 40,188    $     -    $(37,025)   $ (1,026)   $  2,148
                                                           ======    ====   ========    =======    ========    ========    ========
</TABLE>

            See notes to condensed consolidated financial statements

                                       5

<PAGE>


                        CLAIMSNET.COM INC. AND SUBSIDIARY
                 CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
                                 (In thousands)
                                   (Unaudited)

<TABLE>
<CAPTION>

                                                        Six Months Ended
                                                            June 30,
                                                       2001       2000
                                                    ---------   --------
<S>                                                 <C>         <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
   Net loss                                         $ (2,722)   $(11,243)
   Adjustments to reconcile net loss to net cash
   used by operating activities:
     Depreciation and amortization                       317         700
     Provision for doubtful accounts                       6          23
     Amortization of deferred sales discounts             78         157
     Write down of net deferred charges on
       McKesson contract                                 356           -
     Loss on sale of assets                               16           -
     Purchased Research and Development
       in exchange for common stock                        -       6,154
     Non-cash compensation for services                   67           -
     Changes in operating assets and liabilities:
          Accounts receivable                            144         (49)
       Prepaid expenses and other current assets          11           8
       Accounts payable, accrued expenses and
          other current liabilities                     (172)      1,482
                                                    --------    --------
   Net cash used in operating activities              (1,899)     (2,768)
                                                    --------    --------
CASH FLOWS FROM INVESTING ACTIVITIES:
   Sales of marketable securities                          -       3,582
   Purchases of property and equipment                   (29)       (499)
   Proceeds from sale of property and equipment           11           -
   Acquisition cost - HealthExchange assets                -      (3,478)
                                                    --------    --------
   Net cash used in investing activities                 (18)       (395)
                                                    --------    --------
CASH FLOWS FROM FINANCING ACTIVITIES:
   Increase in note payable to affiliate                 400           -
   Payment of note payable to affiliate                 (400)          -
   Proceeds from issuance of common stock              3,271       3,300
                                                    --------    --------
   Net cash provided by financing activities           3,271       3,300
                                                    --------    --------
NET INCREASE (DECREASE) IN CASH AND EQUIVALENTS        1,354         137
CASH AND EQUIVALENTS, BEGINNING OF PERIOD              1,132       3,021
                                                    --------    --------
CASH AND EQUIVALENTS, END OF PERIOD                 $  2,486    $  3,158
                                                    ========    ========
</TABLE>

                                  6
<PAGE>

                        CLAIMSNET.COM INC. AND SUBSIDIARY
           CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
                                 (In thousands)
                                   (Unaudited)
<TABLE>
<CAPTION>

                                                           Six Months Ended
                                                               June 30,
                                                          2001            2000
                                                     -----------    -----------

<S>                                                    <C>           <C>
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Common stock issued for services                       $       42            -
                                                       ==========     ========

Common stock warrants issued for services              $       57            -
                                                       ==========     ========

Issuance of common stock for investment in Health-
Exchange assets                                        $        -     $  6,375
                                                       ==========     ========
</TABLE>

























            See notes to condensed consolidated financial statements.

                                        7

<PAGE>


                        CLAIMSNET.COM INC. AND SUBSIDIARY
              Notes to Condensed Consolidated Financial Statements

1.   BASIS OF PRESENTATION

     In the opinion of management, the accompanying unaudited condensed
     consolidated financial statements include all necessary adjustments
     (consisting of normal recurring accruals) and present fairly the
     consolidated financial position of Claimsnet.com inc. (the "Company") and
     subsidiaries as of June 30, 2001 and the results of its operations and cash
     flows for the three months and six months ended June 30, 2001 and 2000, in
     conformity with generally accepted accounting principles for interim
     financial information applied on a consistent basis. The results of
     operations for the three and six months ended June 30, 2001 are not
     necessarily indicative of the results to be expected for the full year.

     Certain information and footnote disclosures normally included in financial
     statements prepared in accordance with generally accepted accounting
     principles have been omitted. These financial statements should be read in
     conjunction with the audited consolidated financial statements and notes
     thereto included in the Company's Annual Report on Form 10-K for the year
     ended December 31, 2000, as filed with the Securities and Exchange
     Commission on April 14, 2001.

2.   TRANSACTIONS WITH MCKESSON CORPORATION

     On April 12, 2001, the Company entered into an agreement with McKesson
     Corporation (McKesson) which superseded the October 1999 agreement. Under
     the 1999 Development and Services Agreement the Company (a) issued a three
     year warrant to McKesson to purchase 819,184 shares of common stock at
     $7.00 per share, (b) received fees for the development of a private label
     claims processing and statement processing internet application for
     McKesson, (c) received one of three scheduled license fee payments for use
     of the McKesson internet application, (d) received monthly support fees for
     dedicated private label system hosting, operation and support services
     commencing at the date of acceptance of the McKesson internet application,
     and (e) received transaction fees for claims and statements processed by
     the McKesson internet application. Under the new agreement, (a) McKesson
     acquired 1,514,285 shares of common stock at $1.75 per share for net
     proceeds of $2,650,000, (b) McKesson paid a one-time fee of $200,000 (c)
     the stock purchase warrant originally issued to McKesson in October 1999
     was cancelled, (d) McKesson retained a license to use the McKesson internet
     application to process statements and claims without additional license fee
     payments, (e) McKesson agreed to eliminate the need for dedicated private
     label system hosting, operation, and support services and the Company
     agreed to provide standard system hosting, operation, and support services
     without the payment of future monthly support fees, (f) the Company will
     receive fees for transactions processed by the McKesson internet
     application, (g) the Company and McKesson agreed to use best efforts to
     expand the scope of the license agreement to include additional claim
     types, and (h) the Company and McKesson agreed to use best efforts to
     pursue other unspecified business opportunities. Under a separate
     agreement, the Company has contracted for McKesson processing services to
     print patient statements and submit claims to payers for certain customers,
     for which the Company pays McKesson fees for some transactions and shares
     third party revenues for other transactions.

     Pursuant to the October 1999 agreement, through March 31, 2001 the Company
     (a) received payments in the aggregate amount of $2,202,000 (of which
     approximately $1,200,000 was received in December 2000) related to
     development and license fee provisions, which were recorded as deferred
     revenue and were being accounted for by amortizing the total amount,
     received and to be received, of approximately $4,500,000 ratably over the
     expected contract life of 65 months, (b) expended $428,000 related to
     development and implementation costs, which was recorded as software
     development costs on the balance sheet, and was being amortized ratably
     over the expected contract period of 65 months, and (c)recorded in equity a
     capital contribution and an offsetting deferred sales discount in the
     amount of $1,700,000 for the imputed value of the warrant, which was being
     amortized ratably over the expected contract period of 65 months. As of
     March 31, 2001 the Company had amortized $1,187,000 of the deferred revenue
     into revenue, $112,000 of the deferred development costs into cost of
     revenues, and $445,000 of the deferred sales discount as a reduction of
     revenues, leaving balances of $1,015,000, $316,000 and $1,255,000,
     respectively. As of March 31, 2001, the Company accrued the $200,000
     payment received in April in connection with the contract modification as
     additional deferred revenue. As a result of the April 2001 modification of
     the 1999 contract with McKesson, as of March 31, 2001 the Company offset
     the remaining deferred sales discounts against the remaining deferred
     revenue. The

                                     8


<PAGE>

     remaining software development costs of $316,000 were written off to cost
     of revenue. Although the new agreement with McKesson permits them to
     continue to use the software developed specifically to process their
     transactions, there was no requirement for them to use the system and no
     ability to project future transaction revenues.















                                        9


<PAGE>

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results
        of Operations


RESULTS OF OPERATIONS FOR THREE AND SIX MONTHS ENDED JUNE 30, 2001 COMPARED TO
THREE AND SIX MONTHS ENDED JUNE 30, 2000.

REVENUES

Revenues in the three months ended June 30, 2001 were $263,000 compared to
$330,000 in the three months ended June 30, 2000, representing a decrease of
20%. Total revenues in the second quarter 2000 included $131,000 in license fees
related to the original agreement with McKesson Corporation for which there was
no corresponding revenue in the current quarter. Revenue from all sources other
than the McKesson license fees increased 32% to $263,000 from $199,000 in the
three months ended June 30, 2001 compared to 2000. Revenues from other sources
for the three months ended June 30, 2001 were comprised of $171,000 from
transaction-based fees, $57,000 from subscription fees, and $35,000 from
implementation and other fees. Revenues from other sources for the three months
ended June 30, 2000 were comprised of $134,000 from transaction-based fees,
$27,000 from subscription fees, and $38,000 from implementation and other fees.

Revenues in the six months ended June 30, 2001 were $795,000 compared to
$610,000 in the prior year period, representing a 30% increase. License fees,
and support fees related to the original agreement with McKesson, were $289,000
and $262,000 for the six months ended June 30, 2001 and 2000, respectively.
Revenue from all sources other than the McKesson license and support fees
increased 45% to $506,000 in the six months ended June 30, 2001 from $348,000 in
the year earlier period. Revenues from other sources for the six months ended
June 30, 2001 were comprised of $317,000 from transaction-based fees, $107,000
from subscription fees, and $82,000 from implementation and other fees. Revenues
from other sources for the six months ended June 30, 2000 were comprised of
$239,000 from transaction-based fees, $56,000 from subscription fees and $53,000
from implementation and other fees.

The Company processed 1,572,000 transactions during the three months ended June
30, 2001, compared with 1,194,000 transactions in the year-earlier quarter, an
increase of 32%. Transactions increased 23% to 3,006,000 from 2,448,000 for the
six months ended June 30, 2001 and 2000, respectively. The increase was
attributable to internal growth in the number of accounts and healthcare
providers subscribing to the Company's services. Additionally, 91% of all
transactions were for physician and dental claim submission services and 9% were
for patient statement processing services. The Company had 440 accounts
processing transactions for 3,700 providers at June 30, 2001 compared with 378
accounts and 3,005 providers at June 30, 2000, representing increases of 16% and
23%, respectively.

Transaction-based revenue averaged $0.11 per transaction for the six months
ended June 30, 2001 as compared with $0.10 per transaction for the six months
ended June 30, 2000. Revenue per transaction for the 1,491,000 commercial
electronic claims averaged $0.03 during the current six-month period compared to
1,316,000 commercial claims at $0.04 for the prior year period. Revenue per
transaction averaged $0.08 per transaction for the 1,097,000 and 854,000
Medicare and Medicaid claims processed during the six months ended June 30, 2001
and 2000, respectively. Average revenue per transaction for the 175,000 paper
claims was $0.48 during the six months ended June 30, 2001 compared to 176,000
paper claims which averaged $0.46 during the quarter ended June 30, 2000. The
Company processed 242,000 patient statements during the current six months
compared to 102,000 in the same year-earlier period.

                                       10

<PAGE>


COST OF REVENUES

Cost of revenues in the three months and six months ended June 30, 2001 were
$565,000 and $1,475,000, compared with $942,000 and $1,769,000 in the prior year
periods, representing decreases of 40% and 17%, respectively. The four
components of cost of revenues are data center expenses, transaction processing
expenses, customer support operation expenses and software amortization. Data
center expenses were $86,000 for the three months ended June 30, 2001 compared
with $99,000 for the same period in 2000, representing a 13% decrease.
Transaction processing expenses decreased by 6% to $131,000 in 2001 compared to
$139,000 in the second quarter of 2000. These two transaction-based expense
categories combined decreased 9% despite a 32% increase in total transactions
processed, primarily due to improved management of transaction processing
contracts and data center usage. Customer support operations expense decreased
by 48% to $277,000 in the second quarter of 2001 from $534,000 in the second
quarter of 2000, while the number of accounts and providers served at the end of
each quarter increased 16% and 23%, respectively. This decrease was attributable
to cost containment initiatives implemented at the beginning of the year, which
significantly reduced operating expenses in all areas. Software and deferred
development cost decreased 58% to $71,000 in the current quarter from $170,000
in the year-earlier period. This decrease reflects completion of amortization
for earlier versions of software for customer use and first quarter write down
of unamortized deferred development costs


OPERATING EXPENSES

Research and development expenses were $178,000 and $360,000 in the three months
and six months ended June 30, 2001, compared with $753,000 and $984,000 in the
three months and six months ended June 30, 2000, representing decreases of 76%
and 63%, respectively. Research and development expenses are comprised of
personnel costs and related expenses. Current expense levels reflect cut backs
in personnel and other cost containment efforts. Prior period expenses included
development efforts for the HealthExchange products which were curtailed at
year-end. There were no software development expenses capitalized during the
current quarter, and minimal development costs associated with the McKesson
development project were capitalized in the prior year period. Development
efforts during the current quarter were primarily focused on continuous
incremental enhancements to the Company's proprietary software system.

Purchased research and development in the period ended June 30, 2000 reflected
the charge to operations associated with the acquisition of HealthExchange
assets during that quarter.

Amortization of intangibles recorded in the quarter ended June 30, 2000 was
related to HealthExchange assets, which were fully impaired or written off by
year-end.

Selling, general and administrative expenses were $946,000 in the three months
ended June 30, 2001, compared with $1,655,000 in the same period of 2000, a
decrease of 43%. Selling, general and administrative expenses decreased 31% to
$1,704,000 from $2,913,000 for the six months ended June 30, 2001 and 2000,
respectively. The $709,000 quarter-to-quarter decrease includes decreases in
sales and marketing, technology infrastructure and other administrative expenses
due to cuts in personnel costs, office rent, telephone expenses, and outside
professional fees as part of the Company's cost containment strategy implemented
at the start of the year. The quarter ended June 30, 2000 reflected a higher
number of people in sales, marketing and general administration as well as
administrative costs for the HealthExchange asset acquisition and subsequent
operations.

OTHER INCOME

Interest income of $27,000 and $33,000 was provided in the three and six months
ended June 30, 2001 from investment of excess cash in money market instruments.
Interest income of $23,000 and $124,000 in the three and six months ended June
30, 2000 was provided by investment of excess cash in money market instruments
and marketable securities.


                                       11

<PAGE>


LIQUIDITY AND CAPITAL RESOURCES

Net cash used in operating activities of $1,899,000 in the six months ended June
30, 2001 was primarily related to net operating losses of $2,722,000 plus
changes in working capital of $17,000, less: depreciation of $317,000, non-cash
write downs and amortization of $434,000 associated with the McKesson contract
renegotiation, non-cash compensation for services of $67,000, loss on sale of
assets of $16,000, and provision for doubtful accounts of $6,000.

Net cash used in operating activities of $2,768,000 for the six months ended
June 30, 2000 was primarily related to net operating losses of $11,243,000,
less; purchased research and development of $6,154,000 associated with the
HealthExchange acquisition, depreciation of $700,000, provision for doubtful
accounts of $23,000, amortization of deferred sales discounts of $157,000
related to the McKesson Development and Services contract, and changes in
working capital of $1,441,000.

The decrease in net cash used in operating activities between the periods was
primarily related to prior year expenditures to acquire and further develop the
HealthExchange assets, and the cost containment strategy implemented at the
beginning of the current year, which reduced salaries, consulting, rent,
telephone and other operating expenses.

Net cash used in the current period by investing activities was $18,000. Cash
was provided in the current period from the sale of assets which had a net book
value of $27,000 and generated a loss of $16,000. Net cash of $29,000 was used
in investing activities to purchase equipment and software.

Net cash used in investing activities in the period ended June 30, 2000 was
$395,000. Cash was provided by sales of marketable securities of $3,582,000. Net
cash of $3,478,000 was used for the purchase of HealthExchange assets, and
$499,000 for other software and equipment.

In June 2001, the Company issued 16,000 shares of common stock valued at $42,000
to New York Capital AG in connection with an agreement for professional services
to be rendered in 2001. The Company recognized expense of $10,000 in the current
period for services rendered and will recognize the remaining expense in the
next quarter.

In April 2001, the Company entered into an agreement with McKesson by which
McKesson acquired 1,514,285 shares of common stock at $1.75 per share for net
proceeds of $2,650,000 and the stock purchase warrant originally issued to
McKesson in 1999 was cancelled. No registration rights were granted to McKesson
for the shares acquired.

In March 2001, the Company entered into a loan agreement with American Medical
Finance, Inc., a related party, in the amount of $400,000. Principal and
interest, at 9.5% per annum on the unpaid principal, of $407,000 were repaid in
May 2001.

In March 2001, the Company completed the private placement of 400,000 shares of
common stock to an accredited investor at $1.75 per share for net proceeds of
$630,000. In April 2001, the Company issued warrants to purchase 40,000 shares
of common stock to financial advisors that assisted the Company with the
negotiation and structuring of such investment. The warrants are immediately
exercisable at a price of $1.75 per share and expire on the second anniversary
of the date of grant. The stock price on the date of grant was $1.74 per share.
The warrants are fully vested and issued for services rendered in the current
period. The Company recognized a charge to earnings of $57,000, which was equal
to the imputed value of the warrants, estimated at $1.41 per share using the
Black-Scholes valuation method (using the following assumptions: life of two
years, risk free rate of 5.10 percent, no dividends during the term, and a
volatility of 1.459).

In January 2001, the Company granted employees options to purchase an aggregate
of 385,500 shares of common stock under the 1997 Stock Option Plan. The options
were issued at a price of $1.25 per share, the market price on the date of
grant, expire on the tenth anniversary of the grant, and vest on the first
anniversary of the grant.

In August 2000, the Company completed the private placement of 270,000 shares of
common stock at $3.50 per share for net proceeds of $927,000 to various
accredited investors. In connection with the financing, the Company also issued
warrants to purchase 270,000 shares of common stock at a price of $4.60 which
expire in May 2002 and warrants to purchase 270,000 shares of common stock at a
price of $5.60 which expire in July 2002.

In June 2000, the Company completed a private placement of 1,000,000 shares of
common stock to an accredited investor at $3.00 per share for net proceeds of
$2,982,000.



                                     12

<PAGE>

In May 2000, the Company completed a private financing in the amount of $300,000
with the sale of 100,000 shares of common stock to American Medical Finance,
Inc., a related party and the owner of record of 381,603 shares of common stock
prior to the transaction. Bo W. Lycke, the Chairman of the Board, President and
Chief Executive Officer of the Company, Robert H. Brown, Jr., a Director of the
Company, and Ward L. Bensen, a Director of the Company, control 71.1%, 17.7%,
and 11.2%, respectively, of the outstanding common stock of American Medical
Finance, Inc.

In April 2000, the Company issued 1,200,000 shares valued at $6,376,000 to
acquire certain assets from VHx Company. In December 2000, pursuant to
provisions of the asset purchase agreement, the Company withdrew from escrow and
returned to its treasury 888,000 shares at a value of $1,415,000, and issued
244,000 shares valued at $389,000 from treasury stock to John Deere Health, a
major creditor, in satisfaction of debt owed by VHx Company.

Except as otherwise indicated, in each of the security issuances referenced
above, we provided certain rights to register resale of the shares at our
expense under the Securities Act of 1933. Except as indicated, no sales of
securities involved the use of an underwriter and no commissions were paid in
connection with the sale of any securities. Except as otherwise indicated, the
proceeds from each of the private placements referenced above was used for
general corporate purposes. The certificates evidencing the common stock issued
in each of the transactions referenced above were appropriately legended.

The offer and sale of the securities in each of the private placements
referenced above was exempt by virtue of Section 4(2) of the Securities Act of
1933 and the rules promulgated thereunder. Each of the offerees and investors in
such private placements provided representations to us that they were each
"accredited investors," as defined in Rule 501 under the Securities Act of 1933,
as well as highly sophisticated investors, and (ii) some of the investors in the
2000 private placements were existing stockholders of us at the time of such
transaction. Each investor in such private placements, whether a new investor or
existing investor, was afforded the right to conduct a complete due diligence
review of us if they so desired, and was offered the opportunity to ask
questions of, and receive answers from Claimsnet.com.

On May 4, 2001 the Company filed a registration statement on form S-3 to
register 3,076,229 previously unregistered outstanding shares of its common
stock. On July 2, 2001 the Company filed an amended S-3 by which it increased
the number of shares being registered to 3,092,229.

The Company is currently seeking additional funding. Management cannot predict
whether this additional financing will be in the form of equity or debt, or be
in another form. Necessary additional capital may not be available on a timely
basis or on acceptable terms, if at all. The Company believes that its available
cash resources, together with anticipated revenues from operations, will be
sufficient to satisfy its capital requirements through December 31, 2001. This
belief is based on the existence of cash and equivalents of $2,077,000 at July
31, 2001, less $2,002,000 of estimated cash expenditures for the five months
from August 1, 2001 through December 31, 2001. The estimated cash expenditures
for the five months from August 1, 2001 through December 31, 2001 are based upon
average actual results for January through July 2001, adjusted for the effect of
the restructured agreement with McKesson, and excluding a $500,000 disputed
accrued liability which is not expected to require a cash settlement in 2001.
Some of these assumptions may prove to be incorrect. As a result, financial
resources may not be sufficient to satisfy the Company's capital requirements
for this period. In any of these events, the Company may be unable to maintain
its current level of operations, implement current plans for expansion or to
repay debt obligations as they become due. If current plans can not be
successfully implemented, the Company may be forced to significantly reduce
operating expenses to a point which would be detrimental to business operations,
curtail research and development activities, sell certain business assets or
discontinue some or all of our business operations, or take other actions which
could be detrimental to business prospects and result in charges which could be
material to its operations and financial position. In the event that any future
financing should take the form of equity securities, the holders of the common
stock may experience additional dilution.

RECENT ACCOUNTING PRONOUNCEMENTS

In June 1998, the Financial Accounting Standards Board issued Standard No. 133
"Accounting for Derivative Instruments and Hedging Activities". SFAS 133
establishes accounting and reporting standards for derivative instruments,
including certain derivative instruments embedded in other contracts,
(collectively referred to as derivatives) and for hedging activities. SFAS 133
is effective for all fiscal quarters of all fiscal years beginning after June
15, 2000.

                                       13

<PAGE>

Claimsnet's adoption of SFAS 133 effective January 1, 2001 had no material
impact on its financial position or results of operations.

CERTAIN FACTORS THAT MAY AFFECT FUTURE RESULTS

Information contained or incorporated by reference in this periodic report on
Form 10-Q and in other SEC filings by the Company contains "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements are subject to various risks and
uncertainties that could cause actual results to vary materially from those
projected in such forward-looking statements. These risks and uncertainties are
discussed in more detail in the Company's Form 10-K which was filed with the
Securities and Exchange Commission on April 16, 2001. No assurance can be given
that future results covered by the forward-looking statements will be achieved.















                                       14

<PAGE>



                           PART II - OTHER INFORMATION

ITEM 6.   EXHIBITS AND REPORTS ON FORM 8-K

(b)  REPORTS:

     During the quarter ended June 30, 2001, the Company filed reports on form
     8-K dated April 5, 2001, April 18,2001 and May 16, 2001, containing
     information under item 5.


















                                     15

<PAGE>




                                   SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


CLAIMSNET.COM INC.
(Registrant)


By:       /s/ Bo W. Lycke
         -----------------------------
         Bo W. Lycke
         President and
         Chief Executive Officer, on
         behalf of the Registrant


By:       /s/ Paul W. Miller
         -----------------------------
         Paul W. Miller
         Chief Financial Officer


October 2, 2001

















                                       16